JAK1 and acute graft versus host disease: Ruxolitinib, a JAK1 inhibitor, is approved for the treatment of myelofibrosis (Zhang et al., 2022) and acute graft-versus-host disease (Malard et al., 2023) and has been demonstrated to regulate the immune microenvironment by inhibiting myeloproliferation.